Who are CHF 1535 100/6 pMDI 2 months's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ICS/LABA and Montelukast, ICS/LABA medication, CHF1535 200/6 µg pMDI, Foraseq®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf-1535-100-6-pmdi-2-months.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

CHF 1535 100/6 pMDI 2 months — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHF 1535 100/6 pMDI 2 months (CHF 1535 100/6 pMDI 2 months) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ICS/LABA combination. Area: Respiratory/Pulmonology.

phase 3 ICS/LABA combination Glucocorticoid receptor (ICS component); Beta-2 adrenergic receptor (LABA component) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

CHF 1535 100/6 pMDI 2 months (CHF 1535 100/6 pMDI 2 months) — Chiesi Farmaceutici S.p.A.. CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CHF 1535 100/6 pMDI 2 months TARGET	CHF 1535 100/6 pMDI 2 months	Chiesi Farmaceutici S.p.A.	phase 3	ICS/LABA combination	Glucocorticoid receptor (ICS component); Beta-2 adrenergic receptor (LABA component)
ICS/LABA and Montelukast	ICS/LABA and Montelukast	The First Affiliated Hospital of Guangzhou Medical University	marketed	ICS/LABA combination with leukotriene receptor antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1)
ICS/LABA medication	ICS/LABA medication	GlaxoSmithKline	marketed	ICS/LABA combination	Beta-2 adrenergic receptor (LABA component); glucocorticoid receptor (ICS component)
CHF1535 200/6 µg pMDI	CHF1535 200/6 µg pMDI	Chiesi Farmaceutici S.p.A.	phase 3	ICS/LABA combination (Inhaled Corticosteroid/Long-Acting Beta-2 Agonist)	Glucocorticoid receptor (beclomethasone); Beta-2 adrenergic receptor (formoterol)
Foraseq®	Foraseq®	Eurofarma Laboratorios S.A.	phase 3	ICS/LABA combination	Glucocorticoid receptor; Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ICS/LABA combination class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
Eurofarma Laboratorios S.A. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF 1535 100/6 pMDI 2 months — Competitive Intelligence Brief. https://druglandscape.com/ci/chf-1535-100-6-pmdi-2-months. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab